Arès To Lead Up Pharmascience In 2023 After Leaving Sandoz
Former Sandoz VP For Biosimilars Replaces Long Serving David Goodman
Martin Arès is to return to his native Canada early in the new year to take the top job at local generics player Pharmascience, after seven years with Sandoz.
You may also be interested in...
Pharmascience has failed in a two-pronged validity challenge to a key patent shielding Janssen’s Invega Sustenna treatment for schizophrenia.
Apotex has introduced Canada’s first generic version of Eliquis in the form of its Apo-Apixaban product. The launch comes after the firm was also among a wave of Aubagio teriflunomide generics to hit the Canadian market.
In a blow to potential US generic competition, Zydus Cadila has withdrawn its appeal to an unfavorable federal ruling involving a US Farxiga (dapagliflozin) patent.